Addex Therapeutics Ltd (ADXN)
NASDAQ: ADXN · Real-Time Price · USD
5.55
0.00 (0.00%)
Aug 14, 2026, 4:00 PM EDT - Market closed
Addex Therapeutics Revenue
Addex Therapeutics had revenue of 7.69K CHF in the quarter ending March 31, 2026, a decrease of -89.18%. This brings the company's revenue in the last twelve months to 109.50K, down -55.52% year-over-year. In the year 2025, Addex Therapeutics had annual revenue of 172.86K, down -57.84%.
Revenue (ttm)
109.50K CHF
Revenue Growth
-55.52%
P/S Ratio
42.22
Revenue / Employee
36,499 CHF
Employees
3
Market Cap
5.76M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 172.86K | -237.18K | -57.84% |
| Dec 31, 2024 | 410.04K | -1.21M | -74.64% |
| Dec 31, 2023 | 1.62M | 172.23K | 11.92% |
| Dec 31, 2022 | 1.44M | -1.71M | -54.18% |
| Dec 31, 2021 | 3.15M | -725.84K | -18.71% |
| Dec 31, 2020 | 3.88M | 1.05M | 36.89% |
| Dec 31, 2019 | 2.83M | -3.87M | -57.72% |
| Dec 31, 2018 | 6.70M | 6.20M | 1,240.82% |
| Dec 31, 2017 | 499.89K | 373.24K | 294.70% |
| Dec 31, 2016 | 126.65K | -348.97K | -73.37% |
| Dec 31, 2015 | 475.63K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bolt Biotherapeutics | 4.70M |
| BioAtla | 2.00M |
| CollPlant Biotechnologies | 389.00K |
| BioRestorative Therapies | 357.87K |
| Cardio Diagnostics Holdings | 14.45K |
ADXN News
- 5 weeks ago - Addex Therapeutics (ADXN) Reveals Promising Preclinical Results on Sleep-Wake Regulation - GuruFocus
- 5 weeks ago - Addex Research Highlights MGlu7 Modulation As A Novel Pathway In Sleep And Stress Regulation - Nasdaq
- 5 weeks ago - Addex Therapeutics announces publication of new ADX71743 preclinical research - TheFly
- 7 weeks ago - Addex Therapeutics Earnings Call Transcript: Q1 2026 - Transcripts
- 7 weeks ago - Addex Therapeutics Quarterly report: Q1 2026 - Filings
- 7 weeks ago - Addex Therapeutics Earnings release: Q1 2026 - Filings
- 7 weeks ago - Addex Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
- 7 weeks ago - Addex Records Wider Net Loss Of $1.7 Mln; Advances NTX-253 In Phase 1 For Schizophrenia - Nasdaq